GRI
GRI Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.88
+25.76%Aug 24, 2026, 13:05 UTC
GRI Bio announced that three abstracts and an oral presentation highlighting data from its Phase 2a GRI-0621-IPF-02 study have been selected for presentation at the 2026 European Respiratory Society Congress in Barcelona, Spain.
Source:Jun 18, 2026, 12:31 UTC
The U.S. Food and Drug Administration granted Orphan Drug Designation to GRI Bio's drug GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis.
Source: